RU2059615C1 - Производные сульфонамида - Google Patents

Производные сульфонамида Download PDF

Info

Publication number
RU2059615C1
RU2059615C1 SU915001370A SU5001370A RU2059615C1 RU 2059615 C1 RU2059615 C1 RU 2059615C1 SU 915001370 A SU915001370 A SU 915001370A SU 5001370 A SU5001370 A SU 5001370A RU 2059615 C1 RU2059615 C1 RU 2059615C1
Authority
RU
Russia
Prior art keywords
amino
nmr
ppm
fab
chemical formula
Prior art date
Application number
SU915001370A
Other languages
English (en)
Russian (ru)
Inventor
Йюсино Хироси
Уеда Норихиро
Сугуми Хироюки
Нийдзима Дзун
Котаке Иесихико
Окада Тосими
Коянаги Нозому
Ватанабе Татсуо
Асада Макото
Йесимасу Кентаро
Йидзима Атсуми
Нагасу Такеси
Цукахара Каппейи
Китох Киосуки
Original Assignee
Эйсай Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эйсай Ко., Лтд. filed Critical Эйсай Ко., Лтд.
Application granted granted Critical
Publication of RU2059615C1 publication Critical patent/RU2059615C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Glass Compositions (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
SU915001370A 1990-08-20 1991-08-20 Производные сульфонамида RU2059615C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP21871090 1990-08-20
JP218710/90 1990-08-20
JP3850991 1991-03-05
JP38509/91 1991-03-05
JP121041/91 1991-05-27
JP12104191 1991-05-27

Publications (1)

Publication Number Publication Date
RU2059615C1 true RU2059615C1 (ru) 1996-05-10

Family

ID=27289857

Family Applications (1)

Application Number Title Priority Date Filing Date
SU915001370A RU2059615C1 (ru) 1990-08-20 1991-08-20 Производные сульфонамида

Country Status (15)

Country Link
US (6) US5250549A (OSRAM)
EP (1) EP0472053B1 (OSRAM)
KR (1) KR950001686B1 (OSRAM)
CN (2) CN1036650C (OSRAM)
AT (1) ATE167473T1 (OSRAM)
AU (1) AU636239B2 (OSRAM)
CA (1) CA2049496C (OSRAM)
DE (1) DE69129611T2 (OSRAM)
FI (1) FI913815A7 (OSRAM)
HU (1) HUT59663A (OSRAM)
IE (1) IE912936A1 (OSRAM)
NO (1) NO178695C (OSRAM)
NZ (1) NZ239425A (OSRAM)
RU (1) RU2059615C1 (OSRAM)
TW (1) TW206208B (OSRAM)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2234497C2 (ru) * 1998-07-08 2004-08-20 Авентис Фарма Дойчланд Гмбх Серозамещенные n-ариламиды сульфониламинокарбоновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения
RU2239429C2 (ru) * 1996-10-15 2004-11-10 Джи. Ди. Сирл Энд Ко. Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии
EA005376B1 (ru) * 2001-07-13 2005-02-24 Ле Лаборатуар Сервье Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие
RU2283833C2 (ru) * 2001-04-28 2006-09-20 Санофи-Авентис Дойчланд Гмбх Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
RU2333202C2 (ru) * 2003-03-18 2008-09-10 Санофи-Авентис Дойчланд Гмбх 2-(бутил-1-сульфониламино)-n-[1(r)-(6-метоксипиридин-3-ил)-пропил]бензамид, его применение в качестве лекарственного средства, а также содержащие его фармацевтические композиции

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
IT1256354B (it) * 1992-08-31 1995-12-01 Francesca Pelizzoni Derivati della combretastatina ad attivita' anti-tumorale e procedimento per la loro preparazione
ATE225334T1 (de) * 1993-07-26 2002-10-15 Eisai Co Ltd Sulfonamide und sulfonsäure-ester mit je einem trizyclischen heteroring
NZ273073A (en) * 1993-09-10 1996-09-25 Eisai Co Ltd Bicyclic heterocyclic sulphonamide and sulphonic acid ester derivatives and pharmaceutical compositions thereof
DE69523298T2 (de) * 1994-04-06 2002-06-27 D.Western Therapeutics Institute, Nagoya Aminostilbazolderivate und medikament
US5585381A (en) * 1994-06-01 1996-12-17 Kureha Chemical Industry Co., Ltd. Pyrimidine derivatives and pharmaceutical composition
KR100432843B1 (ko) * 1994-12-20 2004-10-14 에프. 호프만-라 로슈 아게 아릴-및헤트아릴-설폰아미드유도체,이들의제조방법및이들의엔도텔린길항제로서의용도
US5900426A (en) * 1995-03-28 1999-05-04 Nippon Zoki Pharmaceutical Co., Ltd. Benzothiazole derivatives
EA001367B1 (ru) * 1996-02-22 2001-02-26 Туларик, Инк. Пентафторбензолсульфонамиды и их аналоги
US6653331B2 (en) * 1996-07-03 2003-11-25 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
US6482860B1 (en) 1996-07-19 2002-11-19 Tularik Inc. Pentafluorobenzenesulfonamides and analogs
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
WO1998054131A1 (en) 1997-05-30 1998-12-03 Nippon Kayaku Kabushiki Kaisha Novel sulfonamide derivatives
DE69827006T2 (de) * 1997-07-25 2005-02-24 Nippon Kayaku K.K. Verbindungen zur förderung der neuronendifferenzierung
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
IL135536A0 (en) * 1997-12-19 2001-05-20 Schering Ag Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
DE19802437A1 (de) * 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
JP4253126B2 (ja) 1998-01-29 2009-04-08 アムジェン インコーポレイテッド Ｐｐａｒ−ガンマ調節剤
CA2335559A1 (en) 1998-06-25 1999-12-29 Tularik Inc. Arylsulfonanilide phosphates
US6153585A (en) 1998-07-20 2000-11-28 Tularik Inc. Arylsulfonanilide derivatives
NZ510435A (en) 1998-09-23 2003-04-29 Tularik Inc Arylsulfonanilide ureas and pharmaceutical use
EP1285911A3 (en) * 1998-09-23 2003-03-26 Tularik Inc. Arylsulfonanilide ureas
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
CA2380078C (en) 1999-07-29 2008-05-06 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides
CA2390557A1 (en) * 1999-11-11 2001-05-17 Kyorin Pharmaceutical Co., Ltd. Solid preparations for oral use
EP1240147A1 (en) 1999-12-21 2002-09-18 Icagen, Inc. Potassium channel inhibitors
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6566380B2 (en) 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
US20050250854A1 (en) * 2000-11-03 2005-11-10 Amgen Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
AUPR738301A0 (en) * 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7833734B2 (en) * 2002-11-26 2010-11-16 Institute Of Virology Of The Slovak Academy Of Sciences CA IX-specific inhibitors
US7550424B2 (en) * 2002-11-26 2009-06-23 Institute Of Virology Slovak Academy Of Sciences CA IX-specific inhibitors
US20050075395A1 (en) * 2003-05-28 2005-04-07 Gary Gordon Continuous dosing regimen
US20040242649A1 (en) * 2003-05-29 2004-12-02 Hagey Anne E. Extended dosing regimen
MXPA05012814A (es) * 2003-05-29 2007-01-25 Abbott Lab Regimen de dosificacion continua con n-(2(2 -((4-hidroxifenil) amino)pirid -3-il)-4- metoxibencen -sulfonamida (abt-751).
US7393873B2 (en) * 2003-07-02 2008-07-01 Merck & Co., Inc. Arylsulfonamide derivatives
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EA200600990A1 (ru) * 2003-12-19 2006-10-27 Пфайзер Инк. Производные бензосульфониламинопиридин-2-ила и родственные соединения в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы 1 типа (11-бета-hsd-1) для лечения диабета и ожирения
EP1722789A2 (en) * 2004-03-08 2006-11-22 Amgen Inc. Therapeutic modulation of ppar (gamma) activity
CA2567838A1 (en) * 2004-05-28 2005-12-15 Abbott Laboratories Treatment of cancer in pediatric patients
KR100839511B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 은-함유 설파제를 디아조화체로 하는 산성 항균 염료와그의 제조 방법 및 그를 이용한 항균 섬유
KR100839512B1 (ko) * 2004-07-02 2008-06-19 주식회사 코오롱 설파제를 디아조화체로 하는 산성 항균 염료 및 그를이용한 항균 섬유
CA2580690A1 (en) * 2004-10-21 2006-05-04 Transtech Pharma, Inc. Bissulfonamide compounds as agonists of galr1, compositions, and methods of use
US20070021470A1 (en) * 2005-01-13 2007-01-25 Jorge Gandarilla Crystalline N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide methanolates
US20070004781A1 (en) * 2005-01-13 2007-01-04 Schmitt Eric A Crystalline N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride
US20060293368A1 (en) * 2005-01-13 2006-12-28 Zhang Geoff G Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide hydrochloride
US7449584B2 (en) 2005-01-13 2008-11-11 Abbott Laboratories Inc. N-(2((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide Crystalline Form 1
US20060293367A1 (en) * 2005-01-13 2006-12-28 Zhang Geoff G Amorphous N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide
US20070021471A1 (en) * 2005-01-13 2007-01-25 Jorge Gandarilla Crystalline N-(2-((4-Hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide ethanolates
JP2008526992A (ja) * 2005-01-13 2008-07-24 アボット・ラボラトリーズ Ｎ−（（２ｚ）−２−（（４−ヒドロキシフェニル）イミノ）−１，２−ジヒドロ−３−ピリジニル）−４−メトキシベンゼンスルホンアミド結晶型２
AU2006204750C1 (en) * 2005-01-14 2012-11-01 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
KR100821898B1 (ko) * 2005-02-23 2008-04-16 주식회사 코오롱 은 함유 항균 산성 염료와 그의 제조 방법 및 그를 이용한항균 섬유
KR100821900B1 (ko) * 2005-09-15 2008-04-16 주식회사 코오롱 항균 산성 염료와 그의 제조 방법 및 그를 이용한 항균섬유
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
GB0524786D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US8519135B2 (en) 2006-07-14 2013-08-27 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2/CCR9
KR101617050B1 (ko) 2007-07-12 2016-05-02 케모센트릭스, 인크. 염증의 치료를 위한 ｃｃｒ2 조절물질로서 융합된 헤테로아릴 피리딜과 페닐 벤젠술폰아마이드
AU2009248923B2 (en) 2008-05-21 2015-01-29 Takeda Pharmaceutical Company Limited Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
PT2374802E (pt) 2008-11-10 2014-07-10 Kyowa Hakko Kirin Co Ltd Inibidor de produção de quinurenina
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012142698A1 (en) * 2011-04-20 2012-10-26 Universite Laval Alkylurea derivatives active against cancer cells
US9834518B2 (en) 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013055793A1 (en) 2011-10-12 2013-04-18 University Of Pittsburg-Of The Commonwealth System Of Higher Education Small molecules targeting androgen receptor nuclear localization and/or level in prostate cancer
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
US20160257657A1 (en) 2013-09-20 2016-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CA2924527C (en) 2013-09-20 2022-07-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Compounds for treating prostate cancer
WO2016007993A1 (en) * 2014-07-16 2016-01-21 University Of South Australia Benzene sulfonamide-based inhibitors of sphingosine kinase
CN112961149A (zh) 2014-08-11 2021-06-15 安吉恩生物医药公司 细胞色素p450抑制剂及其用途
CN107531631B (zh) 2014-12-31 2021-09-03 安吉昂生物医药公司 用于治疗疾病的方法和药剂
US10980806B2 (en) 2016-03-24 2021-04-20 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
CN110177549A (zh) 2016-11-23 2019-08-27 坎莫森特里克斯公司 治疗局灶性节段性肾小球硬化的方法
SG11202002975YA (en) 2017-10-11 2020-04-29 Chemocentryx Inc Treatment of focal segmental glomerulosclerosis with ccr2 antagonists
WO2019139979A2 (en) * 2018-01-09 2019-07-18 The Scripps Research Institute Arylfluorosulfate compounds and methods
WO2019236358A1 (en) * 2018-06-05 2019-12-12 Peter Novak Rubidium compounds for use in the treatment of cancer
CN109331868B (zh) * 2018-09-29 2021-03-26 广东工业大学 一种苯甘氨酸类双官能团催化剂及其制备方法和应用
AU2019470001B2 (en) * 2019-10-11 2024-09-19 Nomax Therapeutics Inc. Rubidium and/or zinc compounds for treating Parkinson's and other neurodegenerative diseases
WO2021150109A1 (en) 2020-01-22 2021-07-29 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Abt-751 and ionizing radiation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2307650A (en) * 1938-11-29 1943-01-05 Nepera Chemical Company Inc Sulphanilamido-amino-pyridines and processes for producing the same
US2202933A (en) * 1939-08-30 1940-06-04 Nepera Chemical Co Inc Sulphanilamido-aminopyridines and process for producing the same
DE1670761A1 (de) * 1966-10-27 1970-12-23 Forsch Borstel Inst Fuer Exper Verfahren zur Herstellung von in 3- oder 5-Stellung durch elektronegative Substituenten substituierten 2-Sulfanil-amido-pyridinen
EP0215200B1 (en) * 1985-06-24 1992-09-09 Merck & Co. Inc. Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases
JPH0610174B2 (ja) * 1986-09-29 1994-02-09 株式会社大塚製薬工場 アミノフエノ−ル誘導体

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2239429C2 (ru) * 1996-10-15 2004-11-10 Джи. Ди. Сирл Энд Ко. Способ применения ингибиторов циклооксигеназы-2 для лечения и профилактики неоплазии
RU2234497C2 (ru) * 1998-07-08 2004-08-20 Авентис Фарма Дойчланд Гмбх Серозамещенные n-ариламиды сульфониламинокарбоновой кислоты, способ их получения (варианты), фармацевтическая композиция и способ лечения
RU2283833C2 (ru) * 2001-04-28 2006-09-20 Санофи-Авентис Дойчланд Гмбх Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции
EA005376B1 (ru) * 2001-07-13 2005-02-24 Ле Лаборатуар Сервье Новые соединения бензолсульфонамида, способ их получения и фармацевтические композиции, их содержащие
RU2333202C2 (ru) * 2003-03-18 2008-09-10 Санофи-Авентис Дойчланд Гмбх 2-(бутил-1-сульфониламино)-n-[1(r)-(6-метоксипиридин-3-ил)-пропил]бензамид, его применение в качестве лекарственного средства, а также содержащие его фармацевтические композиции

Also Published As

Publication number Publication date
KR920004341A (ko) 1992-03-27
NZ239425A (en) 1993-10-26
HUT59663A (en) 1992-06-29
ATE167473T1 (de) 1998-07-15
CA2049496C (en) 1997-02-04
CN1136036A (zh) 1996-11-20
US5610320A (en) 1997-03-11
DE69129611T2 (de) 1998-12-17
US5250549A (en) 1993-10-05
EP0472053B1 (en) 1998-06-17
US5332751A (en) 1994-07-26
EP0472053A3 (en) 1994-08-10
DE69129611D1 (de) 1998-07-23
HU912676D0 (en) 1992-01-28
IE912936A1 (en) 1992-02-26
CN1059519A (zh) 1992-03-18
FI913815A0 (fi) 1991-08-12
NO913207L (no) 1992-02-21
NO178695B (no) 1996-02-05
CN1036650C (zh) 1997-12-10
EP0472053A2 (en) 1992-02-26
US5434172A (en) 1995-07-18
NO913207D0 (no) 1991-08-16
KR950001686B1 (ko) 1995-02-28
US5610304A (en) 1997-03-11
FI913815A7 (fi) 1992-02-21
NO178695C (no) 1996-05-15
US5292758A (en) 1994-03-08
AU8249391A (en) 1992-02-27
CA2049496A1 (en) 1992-02-21
TW206208B (OSRAM) 1993-05-21
AU636239B2 (en) 1993-04-22

Similar Documents

Publication Publication Date Title
RU2059615C1 (ru) Производные сульфонамида
EP0524781B1 (en) Therapeutic amides
CA2559733C (en) Inhibitors of histone deacetylase
US6313153B1 (en) Compositions and methods for treating nephritis and inhibiting TGF -β related conditions using pyridylacrylamide derivatives
HK1003570B (en) Therapeutic amides
AU2003297398A1 (en) Asthma and allergic inflammation modulators
WO2006100502A1 (en) 11-beta-hydroxysteroid dehydrogenase inhibitors
JPH11171848A (ja) 芳香族アミド誘導体
EP0399422A1 (en) Benzocycloalkane derivatives and production thereof
US20040029928A1 (en) Novel propenohydroxamic acid derivatives
JPH11269140A (ja) 分化誘導剤
JP2790926B2 (ja) スルホンアミド誘導体
US20060004197A1 (en) Sulfonamide-based compounds as protein tyrosine kinase inhibitors
JP4191269B2 (ja) 新規なアニリド化合物及びこれを含有する医薬
EP2794009B1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
WO2008024784A1 (en) Alkylsulfonamide-substituted triazoles as matrix metalloprotease inhibitors
US4600709A (en) Benzodioxole derivatives, processes for the manufacture thereof and corresponding pharmaceutical compositions
US5942546A (en) Sulfonyl-N-hydroxyguanidine derivatives
EP4349818A1 (en) Novel oxazole derivative and pharmaceutical composition containing same for prevention or treatment of allergic disease
HK1203430B (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
JPWO2002018326A1 (ja) 新規プロペノヒドロキサム酸誘導体